Tolmar Inc. (responsible for batch release; responsible for secondary packaging; responsible for manufacturing of syringe A, syringe B, final packaging and quality control; responsible for control/testing of the batch; responsible for control/testing of the batch)
UkraineAll drugs from this manufacturer
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as for the treatment of high-risk localized cancer or locally advanced cancer in combination with radiation.
Dosage form: powder for solution for subcutaneous injection
Active substance Dosage leuprorelin 20.87 mg ATC: L02AE02
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as for the treatment of high-risk localized cancer or locally advanced cancer in combination with radiation.
Dosage form: powder for solution for subcutaneous injection
Active substance Dosage leuprorelin 41.7 mg ATC: L02AE02
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as for the treatment of high-risk localized cancer or locally advanced cancer in combination with radiation therapy.
Dosage form: powder for solution for subcutaneous injection
Active substance Dosage leuprorelin 6.96 mg ATC: L02AE02